文献速递细胞病理与分子病理神经与头颈病理

嗜酸细胞为主甲状腺FNA细胞学判读的观察者间差异:173例手术随访与分子检测验证研究

Interobserver variation among cytopathologists in the evaluation of oncocytic cell-predominant thyroid FNA cytology: A validation study of 173 cases with surgical follow-up and correlation with molecular testing.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

本研究让4名细胞病理学家独立评估173例经手术证实的嗜酸细胞为主甲状腺细针穿刺(FNA)细胞学病例(24例AUS,149例FN),并记录结节大小,其中80例进行了Afirma或ThyroSeq分子检测。结果显示,细胞学特征观察者间一致性差异大(高细胞量强、孤立单细胞中等、无胶质和核大小不一差),风险评分特异性高(77%-92%)但敏感性低(6%-22%),分子检测敏感性86%、特异性35%、假阴性率13%-17%。结论认为嗜酸细胞为主FNA的细胞学评估受限,分子检测更客观但特异性低、假阴性率升高。

要点

  • 嗜酸细胞为主FNA细胞学特征观察者间一致性差异大,风险评分特异性高但敏感性低。
  • 细胞病理学家对细胞学特征的一致性并未提高肿瘤或恶性肿瘤的预测能力。
  • Afirma和ThyroSeq分子检测敏感性86%、特异性35%、假阴性率13%-17%。

核心结论

  • 嗜酸细胞为主FNA的细胞学评估受观察者间差异大和与结局关联不一致的限制。
  • 细胞病理学家对特定细胞学特征是否存在的一致性并未增强对肿瘤或恶性肿瘤的预测。
  • 分子检测提供更客观的性能,敏感性高但特异性低且假阴性率升高。
  • 临床医生应知晓嗜酸细胞为主FNA的细胞学和分子检测结果比非嗜酸细胞 counterpart 报告有更大局限性。

研究设计与样本

  • 4名细胞病理学家独立评估173例经手术证实的嗜酸细胞为主FNA细胞学特征(24例AUS,149例FN)。
  • 结节大小单独记录并纳入风险因子评分。
  • 80例子集进行了Afirma或ThyroSeq分子检测。
  • 进行了单变量和多变量逻辑回归及ROC分析。

主要发现

  • 观察者间一致性:高细胞量为强,孤立单细胞为中等,无胶质和核大小不一为差。
  • 风险因子评分显示强一致性,特异性77%-92%,敏感性6%-22%。
  • 病理学家一致性并未更好地预测肿瘤或恶性肿瘤。
  • Afirma和ThyroSeq分子检测总体敏感性86%、特异性35%、假阴性率13%-17%。

关键数值与推荐

  • 风险因子评分特异性77%-92%,敏感性6%-22%。
  • Afirma和ThyroSeq分子检测总体敏感性86%、特异性35%、假阴性率13%-17%。

临床怎么用

  • 临床医生应知晓嗜酸细胞为主FNA的细胞学和分子检测结果比非嗜酸细胞 counterpart 有更大局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interpretation of oncocytic cell-predominant cytologies (OCP) is very challenging as a majority of those cases are diagnosed as indeterminate, including atypia of undetermined significance (AUS) and follicular neoplasm (FN). The authors previously reported a combination of a four-risk factor model highly predictive of neoplasia and malignancy that included four cytologic features and nodule size. However, that model was based on a single cytopathologist (CP) review. The current study assessed the reproducibility of previous findings among several CPs in a larger separate patient cohort, correlated with molecular studies. DESIGN: Four CPs independently evaluated cytologic features of 173 surgically confirmed OCP (24 AUS, 149 FN). Nodule size was recorded separately and incorporated into risk factor scores. A subset of 80 cases underwent molecular testing with Afirma or ThyroSeq. Univariable and multivariable logistic regression and ROC analyses were performed. RESULTS: Interobserver agreements were strong for high cellularity, moderate for isolated single cells, and poor for absent colloid and anisonucleosis. Risk factor scores demonstrated strong agreement, high specificity (77%-92%) and low sensitivity (6%-22%). Pathologist agreement did not better predict neoplasm or malignancy. Afirma and ThyroSeq molecular tests had similar performances with overall sensitivity, specificity, and false-negative rates of 86%, 35%, and 13%-17%, respectively. CONCLUSION: Cytologic evaluation of OCP was limited by wide interobserver variability and inconsistent associations with outcomes. Agreement of CPs on presence of specific cytologic features did not enhance prediction of neoplasm or malignancy. Molecular testing provided more objective performance displaying high sensitivity; however, specificity was low and FNR was elevated. Clinicians should be made aware of the greater limitations associated with cytology and molecular test results of OCP compared to those reported for their nononcocytic counterparts.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Elsheikh TM, Doxtader EE, Golusin M, et al. Interobserver variation among cytopathologists in the evaluation of oncocytic cell-predominant thyroid FNA cytology: A validation study of 173 cases with surgical follow-up and correlation with molecular testing. Cancer Cytopathol. 2026. PMID: 42610750. doi:10.1002/cncy.70143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。